Bayer Weighs Structural Changes But Rules Out Three-Way Split

[ad_1] Updated Nov. 8, 2023 5:34 am ET Bayer Chief Executive Bill Anderson said he is looking at options to overhaul the company’s structure and remove multiple layers of management…

Vivek Ramaswamy Has a Strategy, But It Rests on Trump’s Exit

[ad_1] Updated Jan. 13, 2024 2:20 pm ET WEST DES MOINES, Iowa—For those who speculate about what Vivek Ramaswamy really wants out of his long-shot Republican presidential bid—perhaps a podcast…

WSJ News Exclusive | Novartis Pursuit of Cytokinetics Cools

[ad_1] Updated Jan. 11, 2024 12:47 pm ET Novartis has backed away from its pursuit of Cytokinetics, putting a damper on the prospects of a deal for the promising heart-drug…

WSJ News Exclusive | CVS is Closing Pharmacies Inside Some Target Stores

[ad_1] CVS Health plans to close dozens of pharmacies inside Target stores at a time when pharmacy chains are struggling to grow retail profits. CVS will close the pharmacies between…

It’s Time to Turn on Two-Factor Authentication

[ad_1] We get it. Turning on two-factor authentication for your online accounts can be a pain. But like going to the dentist, it’s just something you have to do. On…

GSK Expands Respiratory Pipeline With Aiolos Bio Buy

[ad_1] Updated Jan. 9, 2024 3:07 am ET GSK is buying biopharmaceutical company Aiolos Bio for up to $1.4 billion in a deal that expands its respiratory pipeline and follows…

WSJ News Exclusive | Tinder Owner Match Draws Elliott Investment

[ad_1] Updated Jan. 8, 2024 9:37 pm ET Elliott Investment Management has built a big stake in Match Group and plans to push the online dating company to take steps…

Johnson & Johnson to Acquire Cancer-Treatment Developer Ambrx for $2 Billion

[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…

WSJ News Exclusive | Novartis in Advanced Talks to Buy Cytokinetics

[ad_1] Updated Jan. 8, 2024 1:14 pm ET Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug, as big pharmaceutical companies continue to snap up…

Boston Scientific To Acquire Axonics For About $3.7 Bln

[ad_1] Boston Scientific will acquire Axonics for about $3.7 billion in cash. The companies said on Monday that Axonics had agreed to be bought for $71 a share. Boston Scientific…